Form 4: Revolution Medicines CFO Sells Shares to Cover Tax Obligations

Revolution Medicines' Chief Financial Officer, Jack Anders, sold 2,635 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Jack Anders, the Chief Financial Officer of Revolution Medicines, sold 2,635 shares of common stock on December 16, 2024.
• The sale was executed at a price of $45.4038 per share.
• This transaction was made to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs).
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 31, 2023.
• Anders also acquired 173 shares through the company's Employee Stock Purchase Plan on November 30, 2024.
• Following the transaction, Anders beneficially owns 96,470 shares, which includes 44,876 RSUs.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction for tax purposes, which is neither particularly positive nor negative. The pre-planned nature of the sale mitigates potential concerns.

Positives

• The sale was part of a pre-arranged trading plan, indicating no unexpected insider selling.
• The CFO also participated in the Employee Stock Purchase Plan, showing continued investment in the company.

Negatives

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, although it was for tax purposes.

Risks

• While the sale was for tax purposes, any significant insider selling could potentially impact investor confidence.
• The market may react negatively to insider sales, even if they are pre-planned.

Industry Context

This type of transaction is common for executives who receive stock-based compensation, as they often sell shares to cover tax liabilities. It is a routine part of executive compensation and financial planning.

Comparison to Industry Standards

• Many executives at publicly traded companies use Rule 10b5-1 plans to manage their stock sales, especially when dealing with stock options or restricted stock units.
• The sale of shares to cover tax obligations is a standard practice across the industry, and the amount sold by Anders is not unusual for a CFO.
• Companies like Amgen and Gilead also see similar transactions from their executives, often timed around vesting periods.

Stakeholder Impact

• The sale of shares by the CFO could have a minor negative impact on shareholder sentiment, although it is a routine transaction.
• The CFO's participation in the Employee Stock Purchase Plan could be seen as a positive sign by employees.

Key Dates

Keywords

insider trading, SEC Form 4, Revolution Medicines, RVMD, Jack Anders, Chief Financial Officer, stock sale, Rule 10b5-1, restricted stock units, tax obligations, employee stock purchase plan